Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 32, Issue 8, 2003, Pages 791-793

  Voena, C ^a   Malnati, M ^b   Majolino, I ^c   Faga G ^b   Montefusco, V ^d   Farina, L ^d   Santoro, A ^c   Ladetto, M ^e   Boccadoro, M ^e   Corradini, P ^d  

^a Instituto Scientifico H S Raffael   (Italy)

^b Dipartimento di Anatomia Umana   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

Author keywords

Allogeneic transplantation; Graft versus myeloma; Multiple myeloma; Real time PCR

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; VINCRISTINE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW; CASE REPORT; CELL KINETICS; CORRELATION ANALYSIS; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MYELOMA CELL; PATIENT MONITORING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

ADULT; BONE MARROW TRANSPLANTATION; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC SCREENING; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION;

EID: 11144355241     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704207     Document Type: Article

References (10)

1. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
2. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
3. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myelogenous leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
4. Voena C, Locatelli G, Castellino C et al. Qualitative and quantitative PCR detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small and large scale Miltenyi cell sorting system. Br J Haematol 2002; 117: 642-645.
5. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
6. Voena C, Ladetto M, Astolfi M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798.
7. Corradini P, Voena C, Astolfi M et al. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596-1602.
8. Martinelli G, Terragna C, Zamagni E et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000; 85: 930-934.
9. Metha J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998; 22: 835-843.
10. Appelbaum F. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.